NO20034308D0 - New tyrokinase inhibitors - Google Patents

New tyrokinase inhibitors

Info

Publication number
NO20034308D0
NO20034308D0 NO20034308A NO20034308A NO20034308D0 NO 20034308 D0 NO20034308 D0 NO 20034308D0 NO 20034308 A NO20034308 A NO 20034308A NO 20034308 A NO20034308 A NO 20034308A NO 20034308 D0 NO20034308 D0 NO 20034308D0
Authority
NO
Norway
Prior art keywords
tyrokinase
inhibitors
new
tyrokinase inhibitors
new tyrokinase
Prior art date
Application number
NO20034308A
Other languages
Norwegian (no)
Other versions
NO20034308L (en
Inventor
Mark D Wittman
Neelakantan Balasubramanian
Upender Velaparthi
Kurt Zimmermann
Mark G Saulnier
Peiying Liu
Xiaopeng Sang
David Bertil Frennesson
Karen M Stoffan
James G Tarrant
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20034308D0 publication Critical patent/NO20034308D0/en
Publication of NO20034308L publication Critical patent/NO20034308L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20034308A 2001-03-28 2003-09-26 New tyrokinase inhibitors NO20034308L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28
PCT/US2002/009402 WO2002079192A1 (en) 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20034308D0 true NO20034308D0 (en) 2003-09-26
NO20034308L NO20034308L (en) 2003-11-26

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034308A NO20034308L (en) 2001-03-28 2003-09-26 New tyrokinase inhibitors

Country Status (25)

Country Link
EP (1) EP1381598A4 (en)
JP (1) JP2004534010A (en)
KR (1) KR20030083016A (en)
CN (1) CN1514833A (en)
AR (1) AR035804A1 (en)
BG (1) BG108206A (en)
BR (1) BR0208373A (en)
CA (1) CA2442428A1 (en)
CZ (1) CZ20032615A3 (en)
EE (1) EE200300475A (en)
GE (1) GEP20053660B (en)
HR (1) HRP20030844A2 (en)
HU (1) HUP0400323A2 (en)
IL (1) IL158041A0 (en)
IS (1) IS6968A (en)
MX (1) MXPA03008690A (en)
NO (1) NO20034308L (en)
PE (1) PE20021015A1 (en)
PL (1) PL373300A1 (en)
RU (1) RU2003131693A (en)
SK (1) SK12002003A3 (en)
UY (1) UY27234A1 (en)
WO (1) WO2002079192A1 (en)
YU (1) YU84603A (en)
ZA (1) ZA200307466B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2003073841A2 (en) 2002-03-01 2003-09-12 Bristol-Myers Squibb Company Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
JP2005532368A (en) * 2002-06-12 2005-10-27 アボット・ラボラトリーズ Melanin-concentrating hormone receptor antagonist
EP1575580A4 (en) * 2002-12-02 2009-06-10 Arqule Inc Method of treating cancers
EP1581539A4 (en) * 2003-01-03 2007-09-19 Bristol Myers Squibb Co Novel tyrosine kinase inhibitors
EP1590339A4 (en) * 2003-01-28 2007-07-25 Smithkline Beecham Corp Chemical compounds
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
DE102004010207A1 (en) 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
PT1740591E (en) 2004-04-02 2009-09-24 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
RU2423351C2 (en) * 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Pyrid-2-ones applicable as protein kinase inhibitors of tec family for treating inflammatory, proliferative and immunologically mediated diseases
US7393667B2 (en) 2005-05-31 2008-07-01 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2396913T3 (en) 2005-08-04 2013-03-01 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2361338T3 (en) 2005-08-29 2011-06-16 Vertex Pharmaceuticals Incorporated PIRID-2-ONAS 3,5-USEFUL DISPOSED AS INHIBITORS OF THE TEC FAMILY OF TIROSINA KINASES NOT LINKED TO RECEIVER.
US7786130B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
WO2007026720A1 (en) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Ring-fused pyrazole derivative
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (en) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. Optically active 2-amino-1-(4-fluorophenyl)ethanol
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US7956190B2 (en) 2007-06-25 2011-06-07 Hoffmann-La Roche Inc. Benzimidazole amido derivatives as kinase inhibitors
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CA2712959C (en) * 2008-01-22 2015-06-23 Vernalis (R & D) Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
EP2283020B8 (en) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
BRPI0922435A2 (en) 2008-12-19 2018-09-11 Sirtris Pharmaceuticals Inc "sirtuine modulatory thiazolopyridine compound, pharmaceutical composition comprising the same and its use."
DE102010001064A1 (en) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
JP2012524119A (en) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ,エルエルシー Preparation of C-pyrazine-methylamine
US8536180B2 (en) * 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
WO2011053779A2 (en) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
ME02663B (en) * 2010-10-06 2017-06-20 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
US8772304B2 (en) * 2010-11-01 2014-07-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
ES2806135T3 (en) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd New bicyclic bromodomain inhibitors
JP6599852B2 (en) 2013-06-21 2019-10-30 ゼニス・エピジェネティクス・リミテッド Novel substituted bicyclic compounds as bromodomain inhibitors
CN105593224B (en) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 Novel quinazolinones as bromodomain inhibitors
CN103936719A (en) * 2014-05-14 2014-07-23 中国药科大学 Preparation method and application of benzimidazoles derivatives
CN108064274A (en) 2014-07-30 2018-05-22 耶达研究及发展有限公司 For cultivating the culture medium of multipotential stem cell
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
JP2017537946A (en) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
EP3283475B1 (en) * 2015-04-16 2019-10-16 Merck Patent GmbH 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
CN117069696B (en) * 2023-08-17 2024-04-26 中国药科大学 Double-target small molecule inhibitor and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
BR0012450B1 (en) * 1999-06-23 2011-08-23 substituted benzimidazoles.
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
EP1381598A4 (en) 2008-03-19
JP2004534010A (en) 2004-11-11
KR20030083016A (en) 2003-10-23
EE200300475A (en) 2004-02-16
WO2002079192A1 (en) 2002-10-10
SK12002003A3 (en) 2004-10-05
EP1381598A1 (en) 2004-01-21
YU84603A (en) 2006-03-03
IS6968A (en) 2003-09-26
CA2442428A1 (en) 2002-10-10
ZA200307466B (en) 2005-01-13
BG108206A (en) 2004-11-30
CN1514833A (en) 2004-07-21
CZ20032615A3 (en) 2004-03-17
UY27234A1 (en) 2002-10-31
PL373300A1 (en) 2005-08-22
GEP20053660B (en) 2005-11-10
HUP0400323A2 (en) 2005-11-28
HRP20030844A2 (en) 2005-08-31
PE20021015A1 (en) 2002-11-10
RU2003131693A (en) 2005-05-10
AR035804A1 (en) 2004-07-14
NO20034308L (en) 2003-11-26
IL158041A0 (en) 2004-03-28
BR0208373A (en) 2005-02-22
MXPA03008690A (en) 2003-12-12

Similar Documents

Publication Publication Date Title
NO20034308D0 (en) New tyrokinase inhibitors
NO20035428D0 (en) New anti-inefficiencies
NO20034992D0 (en) New 4-aninlinoquinoline-3-carboxamides
DE60234125D1 (en) E INHIBITORS
CY2015028I1 (en) AN N-ACYLOSPHIGOSINE GLYCOSYLOTRANSFERASE INHIBITOR
NO20034042D0 (en) Metalloproteinases inhibitors
NO20040014L (en) New connections
NO20041003L (en) New connections
NO20034665D0 (en) New connections
PT1370553E (en) RHOQUINASE INHIBITORS
NO20040933L (en) Novel gamma-secretase inhibitors.
NO20041293L (en) Alkyne-aryl phosphodiesterase-4 inhibitors
DK1534290T3 (en) New kinase inhibitors
EE200300439A (en) Metalloproteinase inhibitors
NO20044588L (en) New connections
NO20044432L (en) New connections
NO20034970D0 (en) New arylheteroalkylamine derivatives
NO20034032L (en) Metalloproteinases inhibitors
NO20034773D0 (en) New phthalazinones
NO20034695D0 (en) New compositions
NO20041185L (en) New cyclohexylsulfones
NO20030274D0 (en) New arylene-sulfonamides
NO20035248D0 (en) New phenylalkyloxy-phenyl derivatives
NO20013535L (en) Neutrophil function inhibitors
NO20025902L (en) New phenylpiperazines

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application